Exact Mass: 299.2282728
Exact Mass Matches: 299.2282728
Found 224 metabolites which its exact mass value is equals to given mass value 299.2282728,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ethylketocyclazocine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
2-Undecyl-4(1H)-quinolinone
2-Undecyl-4(1H)-quinolinone is found in herbs and spices. 2-Undecyl-4(1H)-quinolinone is an alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). Alkaloid from and roots of Ruta graveolens (rue) (as the main component of an inseparable mixture of 2-alkylquinolones contg. the 2-dodecyl, 2-tridecyl and 2-tetradecyl homologues) (Rutaceae). 2-Undecyl-4(1H)-quinolinone is found in herbs and spices.
Pentadecanoylglycine
C17H33NO3 (299.24603079999997)
Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety. Acylglycines 1 possess a common amidoacetic acid moiety and are normally minor metabolites of fatty acids. Elevated levels of certain acylglycines appear in the urine and blood of patients with various fatty acid oxidation disorders. They are normally produced through the action of glycine N-acyltransferase which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine ↔ CoA + N-acylglycine. Pentadecanoylglycine is an acylglycine with C-15 fatty acid group as the acyl moiety.
(2Z)-Non-2-enoylcarnitine
(2Z)-non-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-non-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-non-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-non-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Non-4-enoylcarnitine
Non-4-enoylcarnitine is an acylcarnitine. More specifically, it is an non-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Non-5-enoylcarnitine
Non-5-enoylcarnitine is an acylcarnitine. More specifically, it is an non-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Non-3-enoylcarnitine
Non-3-enoylcarnitine is an acylcarnitine. More specifically, it is an non-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Non-7-enoylcarnitine
Non-7-enoylcarnitine is an acylcarnitine. More specifically, it is an non-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Non-6-enoylcarnitine
Non-6-enoylcarnitine is an acylcarnitine. More specifically, it is an non-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. non-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine non-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Lauroyl Valine
C17H33NO3 (299.24603079999997)
N-lauroyl valine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Valine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Valine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Valine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Myristoyl Alanine
C17H33NO3 (299.24603079999997)
N-myristoyl alanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Alanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Alanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Alanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(+/-)-Ethylketocyclazocine
(1R,9S)-10-(Cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
Benz(cd)indole-6-carboxamide, 4-(dipropylamino)-1,3,4,5-tetrahydro-
3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
3-Pyridinemethanol, 6-amino-alpha-(((1-methyl-4-phenylbutyl)amino)methyl)-
Nylidrin
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
nylidrin
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CA - Sympathomimetics, labour repressants C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CONFIDENCE standard compound; INTERNAL_ID 6; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) INTERNAL_ID 6; CONFIDENCE standard compound; HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu) CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu); Flow Injection CONFIDENCE Reference Standard (Level 1); HBM4EU - science and policy for a healthy future (https://www.hbm4eu.eu)
(+-)-7,8,9-trimethyl-eleocarpine|(+-)-Elaeocarpin|6a,11,12a,12b-tetramethyl-(6ar,12at,12bc)-1,2,3,5,6,6a,12a,12b-octahydro-chromeno[2,3-g]indolizin-12-one
(3S*,4R*,7S*,8S*,11S*,13R*)-8-isocyano-1(12)-cycloamphilectene
tetradeca-2t,6t,8t-12c-tetraen-10-ynoic isobutyl amide
(1S*,3S*,4R*,7S*,8R*,13R*)-7-isocyano-11-cycloamphilectene
3,4-Dihydro,1-hydroxy-Dictyolomide A|dictylomide B
Me ester,(E)-oxime-2-Oxo-hexadecanoic acid
C17H33NO3 (299.24603079999997)
(2E,6E,8E)-2,6,8-Hexadecatrien-10-insaeure-pyrrolidid
(1S*,3S*,4R*,7S*,12S*,13S*)-8-isocyano-10,14-amphilectadiene
(2S,3S,6E)-N,N-dimethyl-2-[(R)-methylsulfinyl]tetradeca-6,13-dien-3-amine|(2S,3S,6E)-N,N-dimethyl-2-[(S)-methylsulfinyl]tetradeca-6,13-dien-3-amine|aplisulfamine A|aplisulfamine B
(3R,5S)-3-methyl-5-((5E)-pentadec-5-ene-7,9-diynyl)-pyrrolidin-2-one
2-Methylpropylamide-(2E,9Z)-2,9-Hexadecadiene-12,14-diynoic acid|hexadeca-2E,9Z-dien-12,14-diynoic acid isobutylamide
N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-3-methyl-2-butenamide
Trachelanthamidine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester
(2E,7Z)-2,7-Hexadecadien-10-insaeure-(2,3-didehydropyrrolidid)|(2E,7Z)-2,7-Hexadecadien-10-insaeure-<2,3-didehydropyrrolidid>
3-hydroxy-C12 homoserine lactone
CONFIDENCE standard compound; INTERNAL_ID 217
4-Cyanophenyl trans-4-pentylcyclohexanecarboxylate
2-(dimethylamino)ethyl 2-methylprop-2-enoate,2-methylpropyl 2-methylprop-2-enoate
1-(TRIISOPROPYLSILYL)-1H-PYRROLO[2,3-B]PYRIDINE-4-CARBONITRILE
1-benzyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester
1-Benzyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine
(S)-[1-([1,4]DIAZEPANE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER
3-Ethyl 1-(2-methyl-2-propanyl) 3-isopropyl-1,3-piperidinedicarbo xylate
Butyl 2-methyl-2-propenoate, N-[(2-methylpropoxy)methyl]-2-propenamide polymer
3,3-DIMETHOXY-ALPHA-METHYLDIPHENETHYLAMINE HYDROCHLORIDE
(S)-ethyl 2-(tert-butoxycarbonylamino)non-8-enoate
6-[4-[2-(dimethylamino)ethyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine
3-HYDROXY-N-((S)-2-OXOTETRAHYDROFURAN-3-YL)DODECANAMIDE
Retinamide
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D000970 - Antineoplastic Agents
3-Cyclopropylmethyl-5-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2H-2,6-methano-benzo[d]azocin-1-one
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
4-(Dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide
(2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
1-Cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]urea
N,N-diethyl-2-(4-methyl-1-piperazinyl)-4-quinazolinamine
2-(beta-Dimethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole
all-trans-Retinoate
A retinoate that is the conjugate base of all-trans-retinoic acid.
18-Hydroxystearate
An omega-hydroxy fatty acid anion that is the conjugate base of 18-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
(2Z,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
9-cis-Retinoate
A retinoate that is the conjugate base of 9-cis-retinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12-Hydroxyoctadecanoate
A hydroxy saturated fatty acid anion that is the conjugate base of 12-hydroxyoctadecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
11-cis-Retinoate
A retinoate that is the conjugate base of 11-cis-retinoic acid, obtaained by deprotonation of the carboxy group; major species at pH 7.3.
(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
10-Hydroxyoctadecanoate
A hydroxy saturated fatty acid anion resulting from the deprotonation of the carboxy group of 10-hydroxyoctadecanoic acid.
(2R)-1-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine
N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide
1-[2-(diethylamino)ethyl]-5,6-dimethyl-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one
N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]acetamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxyoct-4-en-2-yl]nonanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxynon-4-en-2-yl]octanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]propanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxytridec-4-en-2-yl]butanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxyundec-4-en-2-yl]hexanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxydec-4-en-2-yl]heptanamide
C17H33NO3 (299.24603079999997)
N-[(E)-1,3-dihydroxydodec-4-en-2-yl]pentanamide
C17H33NO3 (299.24603079999997)
Propanoic acid, 2-[(1-cyclohexylethyl)carbamoyl]-, trimethylsilyl ester
CID 443409
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics
(R)-10-hydroxyoctadecanoate
A hydroxy monocarboxylic acid anion resulting from the removal of the proton from the carboxy group of (R)-10-hydroxyoctadecanoic acid.
2-Hydroxyoctadecanoate
A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxyoctadecanoic acid (stearic acid), obtained by deprotonation of the carboxy group; major species at pH 7.3.
3-Hydroxy-N-(2-oxotetrahydrofuran-3-yl)dodecanamide
Dehydroabietate
A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.
3-hydroxystearate
A 3-hydroxy fatty acid anion that is the conjugate base of 3-hydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(R)-2-hydroxyoctadecanoate
A 2-hydroxyoctadecanoate that has R configuration. The conjugate base of (R)-2-hydroxyoctadecanoic acid.
(S)-2-Hydroxyoctadecanoate
A 2-hydroxyoctadecanoate that has S configuration. The conjugate base of (S)-2-hydroxystearic acid obtained via deprotonation of the carboxy group; major species at pH 7.3.
11-[(2r,5r,6r)-5-hydroxy-6-methylpiperidin-2-yl]undecanoic acid
C17H33NO3 (299.24603079999997)
(2s,4e,6e,11e)-12-(pyridin-3-yl)dodeca-4,6,11-trien-2-yl acetate
(2e,6e,8e)-1-(pyrrolidin-1-yl)hexadeca-2,6,8-trien-10-yn-1-one
(2e,6e,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid
(2s,4e,6e,8e)-12-(pyridin-3-yl)dodeca-4,6,8-trien-2-yl acetate
(1s,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one
1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one
2-(nonan-8-one)-4-methoxy-quinoline
{"Ingredient_id": "HBIN006130","Ingredient_name": "2-(nonan-8-one)-4-methoxy-quinoline","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15680","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-(nonan-8-one)-n-methyl-4-quinolone
{"Ingredient_id": "HBIN006131","Ingredient_name": "2-(nonan-8-one)-n-methyl-4-quinolone","Alias": "NA","Ingredient_formula": "C19H25NO2","Ingredient_Smile": "CCCCCCC=CCC1=C(C(=O)C2=CC=CC=C2N1O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "15681","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol
3-methyl-5-[3-methyl-3-(4-methylpent-3-en-1-yl)oxiran-2-yl]-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one
(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate
(2e,9z)-n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid
(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate
n-(2-methylpropyl)hexadeca-2,9-dien-12,14-diynimidic acid
(1r,10s,11s)-1,7,10,11-tetramethyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one
(2e,4e,6e)-12-(pyridin-3-yl)dodeca-2,4,6-trien-1-yl acetate
n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbut-2-enamide
n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid
(1s,2s,4s,6r,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol
(2e,6z,8e,12z)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid
(2z,6z,8z,12e)-n-(2-methylpropyl)hexadeca-2,6,8,12-tetraen-10-ynimidic acid
(1s,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r,3s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate
(2s,5e,8e,10e)-12-(pyridin-3-yl)dodeca-5,8,10-trien-2-yl acetate
(1s,2s,4s,6r,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol
(2e,7z)-1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one
(1s,2s,4s,6s,7s,10s,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-12-en-6-ol
(1s,4r,12r,15r)-15-ethyl-4-hydroxy-1λ⁵,11-diazapentacyclo[13.3.1.0¹,¹².0⁴,¹².0⁵,¹⁰]nonadeca-5,7,9-trien-1-ylium
(1s,2s,4s,6s,7s,10r,11r)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-en-6-ol
1-(2,3-dihydropyrrol-1-yl)hexadeca-2,7-dien-10-yn-1-one
(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate
11-(5-hydroxy-6-methylpiperidin-2-yl)undecanoic acid
C17H33NO3 (299.24603079999997)